

Ref. No.P-66/2025-26/26
July 28, 2025

The Relationship Manager,
Department of Corporate Relations
BSE Limited,
P.J. Towers, Dalal Street
Fort, MUMBAI – 400 001

Dear Sir / Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

This is to inform you that 3B BlackBio Dx Ltd. (hereinafter referred to as “3B”) along with its subsidiary TRUPCR® Europe Limited (hereinafter referred to as “TPE”) is pleased to announce that it has entered into a definitive agreement with Avacta Group Plc, London to acquire all the shares of Coris Holding SRL , holding company of Coris Bioconcept SRL (“Coris”) for an upfront cash consideration of £2.15 Million (including net cash & customary working capital adjustments) with an earn-out based on future business performance, of up to £0.615 Million (the “Acquisition”) totaling to £2.765 Million.

3B shall acquire 70% of the total paid-up share capital and TPE shall acquire 30% of the total paid-up share capital by 10th September 2025, and accordingly Coris shall become a subsidiary of the company as per the conditions set out in the Share Purchase agreement signed between the parties.

The details required under Regulation 30 of SEBI LODR Regulations read with the SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed as Annexure I. A business update on the aforesaid acquisition is enclosed as Annexure II for your perusal and information.

Further, pursuant to Regulation 30 (8) of the SEBI LODR Regulations the enclosed disclosures and the business update are also made available on the company’s website.

This is for your information and further dissemination.

Thanking You,
For 3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

Nikhil Kuber Dubey
WholeTime Director
DIN: 00538049

Encl: As above

Annexure-I

Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

| S.No. | Particulars | Details |
|--------------|---|--|
| a) | Name of the Target Entity, details in Brief such as Size, Turnover etc.; | Coris Holdings SRL, Rue Guillaume Fouquet INSES, 11 5032 Gembloux BELGIUM <u>Revenue of Coris Bioconcept SRL, (wholly owned by of Coris Holdings SRL)</u> €5.20 Million (FY'23) €5.22 Million (FY'24) |
| b) | Whether the acquisition would fall within Related Party Transaction(s) and whether the Promoter/ Promoter Group/ Group Companies have any interest in the Entity being acquired? If Yes, nature of interest and details thereof and whether the same is done at "Arm's Length"; | The acquisition does not fall within related party transactions. The promoter / promoter group have no interest in the entity being acquired. |
| c) | Industry to which the Entity being acquired belongs; | In vitro Diagnostics (IVD) |
| d) | Objects and Impact of Acquisition (including but not limited to, Disclosure of Reasons for Acquisition of Target Entity, if its Business is outside the main line of Business of the listed entity); | <ol style="list-style-type: none"> 1. This transaction will strengthen our position in the IVD market globally as the product range complements our existing product portfolio. 2. With the R&D and manufacturing facilities already established in Belgium, this transaction will allow us to add products in our existing portfolio without any delays and further add to the revenue streams. 3. This transaction will also allow us to expand our existing products to the untapped markets, through Coris network thereby allowing us for a faster growth. |
| e) | Brief Details of any Governmental or Regulatory Approvals Required for the Acquisition; | None |
| f) | Indicative Time Period for Completion of the Acquisition; | Acquisition to be completed by 10 th Sept 2025 |
| g) | Consideration - Whether Cash Consideration or Share Swap or any Other Form and Details of the same; | All Cash |
| h) | Cost of Acquisition and/or the Price at Which the Shares are Acquired; | Acquisition of the shares of Coris Holdings LLC will be done at £2.15 Million (including net cash & customary working capital adjustments) with an earn-out based on future business performance, of up to £0.615 Million totaling to £2.765 Million |



| i) | Percentage of Shareholding / Control Acquired and / or Number of Shares Acquired; | <ol style="list-style-type: none">1. 70% Equity Shares will be acquired by 3B BlackBio Dx Limited from Avacta Group Plc, London2. 30% Equity Shares will be acquired by TRUPCR® Europe Limited (subsidiary of 3B BlackBio Dx Limited) Limited from Avacta Group Plc, London | | | | | | | | |
|--------|---|--|------|-----------------|--------|---------------|--------|---------------|--------|---------------|
| j) | Brief Background about the Entity Acquired in terms of Products/Line of Business Acquired, Date of Incorporation, History of last 3 years turnover, Country in which the Acquired Entity has presence and any other Significant Information (in brief); | <p>Coris Holdings SRL , is the 100% parent company of Coris BioConcept SRL which is a limited liability company (<i>société à responsabilité limitée</i>) under the laws of Belgium .Coris Bioconcept SRL is a leading European manufacturer of IVD test kits – under lateral flow assays, primarily focusing on antimicrobial resistance (AMR) diagnostics alongwith respiratory, gastroenteric and blood-borne pathogens (bacteria, viruses and parasites).</p> <p>Details of Revenue:</p> <table border="1" data-bbox="799 875 1305 1010"><thead><tr><th>Year</th><th>Approx. Revenue</th></tr></thead><tbody><tr><td>FY2022</td><td>€5.34 Million</td></tr><tr><td>FY2023</td><td>€5.20 Million</td></tr><tr><td>FY2024</td><td>€5.22 Million</td></tr></tbody></table> | Year | Approx. Revenue | FY2022 | €5.34 Million | FY2023 | €5.20 Million | FY2024 | €5.22 Million |
| Year | Approx. Revenue | | | | | | | | | |
| FY2022 | €5.34 Million | | | | | | | | | |
| FY2023 | €5.20 Million | | | | | | | | | |
| FY2024 | €5.22 Million | | | | | | | | | |

Annexure –II

BUSINESS UPDATE: 3B BLACKBIO DX LIMITED AND TRUPCR® EUROPE LIMITED JOINTLY ACQUIRES 100% STAKE IN CORIS HOLDING SRL, BELGIUM

July 28th 2025, Bhopal, (M.P.) INDIA: 3B BlackBio Dx Ltd. (**3B**) along with its subsidiary TRUPCR® Europe Limited (**TPE**) is pleased to announce that it has entered into a definitive agreement with Avacta Group Plc, London to acquire all the shares of Coris Holding SRL, the parent company of Coris Bioconcept SRL (“**Coris**”) for an upfront cash consideration of £2.15 Million (including net cash & customary working capital adjustments) with an earn-out based on future business performance of up to £0.615 Million payable (the “**Acquisition**”) totaling to £2.765 Million

According to the latest unaudited financial results shared by **Coris**, the company reported unaudited revenue of €5.22 Million for the financial year ended 31st December 2024 (“FY24”), primarily driven by sales from non-COVID products. The company achieved a gross margin of approximately 58.7%. However, **Coris** recorded a negative EBITDA of €0.215 Million its net assets stood at €4.14 Million.

Coris employs a dedicated team of 33 professionals across key functions including R&D, Production, Sales, Marketing, Quality Control, Regulatory Affairs, and Administration. The company operates from a new 2,000 m² facility in Gembloux, Belgium, which houses its R&D and production units, corporate offices, and warehouse.

Coris’ product portfolio comprises *in vitro* diagnostic test kits for AntiMicrobial Resistance (AMR), respiratory, gastroenteric and blood-borne pathogens (bacteria, viruses and parasites), however, it is primarily focused on the antibiotic resistance markers. As part of this portfolio, the company offers a range of rapid lateral flow tests designed to support early and accurate diagnosis at the point of care.

Coris maintains a strong focus on research and development, and a high percentage of expenses is done on R&D , aiming to expand its product portfolio and address emerging diagnostic challenges, particularly in the area of antimicrobial resistance (AMR), with a strong pipeline of AMR products planned to be launched in FY 2026 & 2027, helping to increase Sales & EBITDA in coming years .

Coris also offers a lateral flow test ‘HAT Sero K-Set’ for detecting antibodies specific to *Trypanosoma brucei gambiense* in human whole blood, serum or plasma, a product that holds global monopoly. Coris had also developed and launched the **First European Lateral Flow Test** for detection of COVID, leading to a spike in revenue in FY20 and demonstrating its product development and go to market capability.

Since **3B** also specializes in IVD products, this acquisition is complementary, as both companies share a focus on *in vitro* diagnostics, particularly in antimicrobial resistance (AMR) which is a growing global concern. The combined strengths of **3B** and **Coris** create opportunities to expand sales and market reach by leveraging their global distributor networks. The two companies will work collaboratively to promote and distribute each

other's complementary product lines, enhancing value for partners and customers worldwide.

Mr. Thierry Leclipteux (CEO – Coris Bioconcept SRL) and Mr. Sebastien Goenen (Chief Operational Officer – Coris Bioconcept SRL) say “We are pleased to express our full support for the recent acquisition of Coris BioConcept (Coris) by 3B Blackbio Dx Ltd (3B). This strategic partnership marks an exciting new chapter for our organization, presenting tremendous opportunities for growth, innovation, and enhanced service delivery. We are enthusiastic about working together to build upon our shared strengths and continue delivering high-quality solutions, and as leaders in Antibiotic Resistance detection and rapid tests, we recognize the value and opportunities that 3B will bring to us. Their ambitions and forward-thinking approach align with our mission, and we are confident that this acquisition will strengthen our ability to serve our customers and their patients. In this challenging and competitive world of diagnostic devices, we think that this acquisition will reinforce both entities with synergies in R&D and production as well as an extended and unique portfolio and distribution network. With our experience of nearly 30 years in rapid tests, our pioneer position in AMR and our extended distribution network, we are convinced that Coris will also bring new opportunities to 3B to develop into new domains and regions. We encourage our teams to embrace the opportunities this acquisition presents, as it will unlock new possibilities and drive innovation for the future. We look forward to a prosperous partnership with 3B and TRUPCR® Europe Limited.”

Mr. Dharendra Dubey (Founder CEO – 3B BlackBio Dx Limited) says, “Coris Bioconcept SRL, is a leading European organization in lateral flow assay technology focused on antimicrobial resistance (AMR) diagnostics. This strategic move strengthens our position in the fight against AMR and complements our existing molecular diagnostics portfolio. By combining our expertise in the PCR-based solutions and with Coris' innovation in rapid testing, we are advancing toward our shared vision of faster, accessible, and more accurate diagnostics worldwide.”

About 3B BlackBio Dx Limited:

3B is a research-driven company dedicated to the development, validation, and manufacturing of high-quality *in vitro* diagnostic (IVD) products. Under its brands—TRUPCR®, TRURAPID®, and TRUNGS®—**3B** offers a comprehensive portfolio focused on oncology and infectious disease diagnostics.

With over 14 years of industry expertise and more than 100 successfully launched products, 3B is committed to advancing patient care through innovative and reliable diagnostic solutions. All molecular diagnostic kits are developed and manufactured in compliance with the highest quality standards, backed by ISO 13485:2016 certification through BSI, UK.

3B's subsidiary, **TPE**, based in Manchester, UK, serves as the company's European headquarters. Also ISO 13485 certified through BSI UK, TPE oversees the manufacturing, sales, and marketing of IVD products kits across Europe, Latin America, and Africa, further strengthening 3B's global footprint.

About Coris Bioconcept SRL:

Founded in 1996 and headquartered in Gembloux, Belgium, **Coris** develops, manufactures and distributes *in vitro* diagnostic (IVD) rapid test kits, with a primary focus on lateral flow assays designed for use by healthcare professionals.

Coris is ISO 13485 certified, ensuring the highest standards of quality and regulatory compliance across its operations. The company distributes its products through a global network of distributors in over 60 countries, reaching markets in Europe, Asia, South America, Africa, and Oceania.

For the financial year ending December 31, 2024, Coris reported the following regional revenue distribution: 80% from Europe; 15% from the Americas; 5% from the Middle East, Africa, and Asia-Pacific.